CSNpharm

CSNpharm logo

Csnpharm is committed to providing you with high quality products and outstanding services. We supply over 5000 bioactive compounds in stock, including inhibitors, agonists and natural products for laboratory and scientific use. Csnpharm has always been committed to develop quality products that are validated by NMR, UPLC, LC-MS, GC, Chiral HPLC and so on. We have a professional technical support team for customer service with years of experience in life science. Csnpharm is your reliable partner for scientific research.

Company Website

Product Listing

Tacrolimus 100mg  | ≥99%

CSNpharm

Tacrolimus is a potent immunosuppressive drug often administered to transplant recipient patients and exhibits a variety of adverse cardiovascular effects. Its mechanism of action involves the formation of a high affinity complex (Ki = 0.2 nM) with FK-506 binding protein 12 (FKBP12).

More Information Supplier Page

Tacrolimus 250mg  | ≥99%

CSNpharm

Tacrolimus is a potent immunosuppressive drug often administered to transplant recipient patients and exhibits a variety of adverse cardiovascular effects. Its mechanism of action involves the formation of a high affinity complex (Ki = 0.2 nM) with FK-506 binding protein 12 (FKBP12).

More Information Supplier Page

Tacrolimus Monohydrate 5mg  | ≥98%

CSNpharm

Tacrolimus is a potent immunosuppressive drug often administered to transplant recipient patients and exhibits a variety of adverse cardiovascular effects. Its mechanism of action involves the formation of a high affinity complex (Ki = 0.2 nM) with FK-506 binding protein 12 (FKBP12).

More Information Supplier Page

Tacrolimus Monohydrate 50mg  | ≥98%

CSNpharm

Tacrolimus is a potent immunosuppressive drug often administered to transplant recipient patients and exhibits a variety of adverse cardiovascular effects. Its mechanism of action involves the formation of a high affinity complex (Ki = 0.2 nM) with FK-506 binding protein 12 (FKBP12).

More Information Supplier Page

Tacrolimus Monohydrate 10mg  | ≥98%

CSNpharm

Tacrolimus is a potent immunosuppressive drug often administered to transplant recipient patients and exhibits a variety of adverse cardiovascular effects. Its mechanism of action involves the formation of a high affinity complex (Ki = 0.2 nM) with FK-506 binding protein 12 (FKBP12).

More Information Supplier Page

Tafenoquine 10mg  | ≥97%

CSNpharm

Tafenoquine is an oral active antimalaria drug that is being investigated as a potential treatment for malaria, as well as for malaria prevention.

More Information Supplier Page

Tafenoquine 5mg  | ≥97%

CSNpharm

Tafenoquine is an oral active antimalaria drug that is being investigated as a potential treatment for malaria, as well as for malaria prevention.

More Information Supplier Page

Tafenoquine 1mg  | ≥97%

CSNpharm

Tafenoquine is an oral active antimalaria drug that is being investigated as a potential treatment for malaria, as well as for malaria prevention.

More Information Supplier Page

Tafenoquine 25mg  | ≥97%

CSNpharm

Tafenoquine is an oral active antimalaria drug that is being investigated as a potential treatment for malaria, as well as for malaria prevention.

More Information Supplier Page

TAK-242 5mg  | ≥99%

CSNpharm

TAK-242, a small-molecule-specific inhibitor of Toll-like receptor (TLR)4 signaling, inhibits the production of lipopolysaccharide-induced inflammatory mediators by binding to the intracellular domain of TLR4.

More Information Supplier Page

TAK-242 50mg  | ≥99%

CSNpharm

TAK-242, a small-molecule-specific inhibitor of Toll-like receptor (TLR)4 signaling, inhibits the production of lipopolysaccharide-induced inflammatory mediators by binding to the intracellular domain of TLR4.

More Information Supplier Page

TAK-242 100mg  | ≥99%

CSNpharm

TAK-242, a small-molecule-specific inhibitor of Toll-like receptor (TLR)4 signaling, inhibits the production of lipopolysaccharide-induced inflammatory mediators by binding to the intracellular domain of TLR4.

More Information Supplier Page

TAK-242 10mg  | ≥99%

CSNpharm

TAK-242, a small-molecule-specific inhibitor of Toll-like receptor (TLR)4 signaling, inhibits the production of lipopolysaccharide-induced inflammatory mediators by binding to the intracellular domain of TLR4.

More Information Supplier Page

TAK-242 25mg  | ≥99%

CSNpharm

TAK-242, a small-molecule-specific inhibitor of Toll-like receptor (TLR)4 signaling, inhibits the production of lipopolysaccharide-induced inflammatory mediators by binding to the intracellular domain of TLR4.

More Information Supplier Page

TAK-242 1mg  | ≥99%

CSNpharm

TAK-242, a small-molecule-specific inhibitor of Toll-like receptor (TLR)4 signaling, inhibits the production of lipopolysaccharide-induced inflammatory mediators by binding to the intracellular domain of TLR4.

More Information Supplier Page

TAK-243 10mg  | ≥98%

CSNpharm

TAK-243, also known as MLN7243 and AOB87172, is a small molecule inhibitor of ubiquitin-activating enzyme (UAE), with potential antineoplastic activity.

More Information Supplier Page

TAK-243 5mg  | ≥98%

CSNpharm

TAK-243, also known as MLN7243 and AOB87172, is a small molecule inhibitor of ubiquitin-activating enzyme (UAE), with potential antineoplastic activity.

More Information Supplier Page

TAK-715 10mg  | ≥98%

CSNpharm

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, being 28-fold selective for p38α over p38β, showing no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1.

More Information Supplier Page

TAK-715 5mg  | ≥98%

CSNpharm

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, being 28-fold selective for p38α over p38β, showing no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1.

More Information Supplier Page

TAK-715 1mg  | ≥98%

CSNpharm

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, being 28-fold selective for p38α over p38β, showing no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1.

More Information Supplier Page

TAK-778 10mg  | ≥98%

CSNpharm

TAK-778 is a derivative of ipriflavone and has been shown to induce bone growth in in vitro and in vivo models.

More Information Supplier Page

TAK-778 5mg  | ≥98%

CSNpharm

TAK-778 is a derivative of ipriflavone and has been shown to induce bone growth in in vitro and in vivo models.

More Information Supplier Page

TAK-778 1mg  | ≥98%

CSNpharm

TAK-778 is a derivative of ipriflavone and has been shown to induce bone growth in in vitro and in vivo models.

More Information Supplier Page

Talabostat Mesylate 5mg  | 90%

CSNpharm

Talabostat mesilate is an orally active, specific inhibitor of dipeptidyl peptidases with IC50 of 1 nM for DPP4, including tumor-associated fibroblast activation protein.

More Information Supplier Page

Talabostat Mesylate 25mg  | ≥90%

CSNpharm

Talabostat mesilate is an orally active, specific inhibitor of dipeptidyl peptidases with IC50 of 1 nM for DPP4, including tumor-associated fibroblast activation protein.

More Information Supplier Page

Talabostat Mesylate 1mg  | ≥90%

CSNpharm

Talabostat mesilate is an orally active, specific inhibitor of dipeptidyl peptidases with IC50 of 1 nM for DPP4, including tumor-associated fibroblast activation protein.

More Information Supplier Page

Talabostat Mesylate 10mg  | ≥90%

CSNpharm

Talabostat mesilate is an orally active, specific inhibitor of dipeptidyl peptidases with IC50 of 1 nM for DPP4, including tumor-associated fibroblast activation protein.

More Information Supplier Page

Talabostat Mesylate 50mg  | ≥90%

CSNpharm

Talabostat mesilate is an orally active, specific inhibitor of dipeptidyl peptidases with IC50 of 1 nM for DPP4, including tumor-associated fibroblast activation protein.

More Information Supplier Page